The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
Publications
Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.
The American journal of surgical pathology 2019 Oct;43;1331-1340 — 2019 Oct — 1331-1340
Ishiwata T, Ebata T, Iwasawa S, Matsushima J, Ota S, Nakatani Y, Tsushima K, Tada Y, Tatsumi K, Takiguchi Y
Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP).
Internal medicine (Tokyo, Japan) 2017 Sep 01;56;2311-2315 — 2017 Sep 01 — 2311-2315